Paper · 2026 · Open access
Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy
Zenodo (CERN European Organization for Nuclear Research) · Published 25 October 2026 · DOI 10.5281/zenodo.23631730
In brief
“Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy” is a 2026 paper by Nithin Ganesh Ghorpade and 5 co-authors, published in Zenodo (CERN European Organization for Nuclear Research). OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Zenodo (CERN European Organization for Nuclear Research).
- Citations
- 0
- Authors
- 6
Abstract
Background The field of pharmacogenomics (PGx) deals with the study of the impact of genetic variability on drug responsiveness. PGx serves as the scientific backbone of personalized medicine, providing clinicians with the ability to choose appropriate treatments for patients in accordance with their genetic make-up, thus minimizing the risk of adverse drug events (ADEs). Objective To present a systematic review of the scientific evidence on the scientific basis, clinical utility, safety considerations, barriers to implementation, and the future of pharmacogenomics across various medical fields. Methods Narrative review of peer-reviewed articles written between 2000 and 2024, from such databases as PubMed, Scopus, Embase, Web of Science, and Google Scholar. Results Clinical variation in drug metabolism is caused by polymorphisms in the genes that code for CYP450 enzymes (CYP2D6, CYP2C19, CYP2C9) and other pharmaco genes. Several important gene/drug combinations such as CYP2C19/clopidogrel, VKORC1CYP2C9/warfarin, HLA-B*57:01/abacavir, CYP3A5/tacrolimus, and TPMT/azathioprine have CPIC-approved guidelines for pharmacogenomics. PGx-based prescriptions reduce the need for trial and error, reduce ADR frequency, and improve treatment efficacy in oncology, psychiatry, cardiology, infectious disease management, and transplantation. The recognition by the regulatory authorities is increasing, with FDA including PGx biomarkers in the label of hundreds of drugs. Some challenges that exist include lack of clinician education, absence of standard guidelines, lack of EHR integration and ethical issues regarding genetic privacy and discrimination. Conclusion Pharmacogenomics is changing the approach to medication prescriptions from one based on populations towards individually-tailored genetic prescriptions. Integration into clinical practice, along with AI, EHR, and standardized guidelines will be necessary. Keywords Precision Medicine, Pharmacogenetics, Molecular Targeted Therapy, Electronic Health Records, Drug Prescriptions
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Ghorpade, N. G., Sodhi, E. K., Urs, G. D., Gupta, B. S., Palaksha, S., & Mamadapur, M. (2026). Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.23631730
MLA 9
Ghorpade, Nithin Ganesh, et al. “Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy.” Zenodo (CERN European Organization for Nuclear Research), 2026. https://doi.org/10.5281/zenodo.23631730.
Chicago
Ghorpade, Nithin Ganesh, Eshveen Kour Sodhi, Gagan D Urs, Balaji Sathyanarayana Gupta, Shilpa Palaksha, and Mahabaleshwar Mamadapur. 2026. “Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy.” Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.23631730.
Harvard
Ghorpade, N. G. et al. (2026) ‘Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy’, Zenodo (CERN European Organization for Nuclear Research). doi:10.5281/zenodo.23631730.
IEEE
N. G. Ghorpade, E. K. Sodhi, G. D. Urs, B. S. Gupta, S. Palaksha, and M. Mamadapur, “Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy,” Zenodo (CERN European Organization for Nuclear Research), 2026, doi: 10.5281/zenodo.23631730.
BibTeX
@article{ghorpade2026pharmacogenomics,
title = {{Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy}},
author = {Ghorpade, Nithin Ganesh and Sodhi, Eshveen Kour and Urs, Gagan D and Gupta, Balaji Sathyanarayana and Palaksha, Shilpa and Mamadapur, Mahabaleshwar},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
doi = {10.5281/zenodo.23631730},
url = {https://doi.org/10.5281/zenodo.23631730}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- pharmacogenomics
- personalized medicine
- genetic testing
- adverse drug reactions
- drug metabolism
- cytochrome P450
- CYP2C19
- CYP2D6
Work with this paper
Most-cited papers in Pharmacology, Toxicology and Pharmaceutics
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingOleg Trott, Arthur J. Olson · Journal of Computational Chemistry · 2009 · 39,860 citations
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityGarrett M. Morris, Ruth Huey, William Lindstrom and 4 more · Journal of Computational Chemistry · 2009 · 26,508 citations
- Development and testing of a general amber force fieldJunmei Wang, Romain M. Wolf, James W. Caldwell and 2 more · Journal of Computational Chemistry · 2004 · 20,080 citations
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy and 1 more · Advanced Drug Delivery Reviews · 2001 · 19,638 citations
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesAntoine Daina, Olivier Alain Michielin, Vincent Zoete · Scientific Reports · 2017 · 19,557 citations
All highly cited Pharmacology, Toxicology and Pharmaceutics papers
Questions about this paper
How do I cite this paper in APA style?
Ghorpade, N. G., Sodhi, E. K., Urs, G. D., Gupta, B. S., Palaksha, S., & Mamadapur, M. (2026). Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.23631730
How many times has this paper been cited?
0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Zenodo (CERN European Organization for Nuclear Research): sign in and open the full text from this page.
Who wrote this paper?
Nithin Ganesh Ghorpade, Eshveen Kour Sodhi, Gagan D Urs, Balaji Sathyanarayana Gupta, Shilpa Palaksha, Mahabaleshwar Mamadapur.
What is the DOI of this paper?
10.5281/zenodo.23631730, permanently at https://doi.org/10.5281/zenodo.23631730. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.